Between 1957 and 1961, the sedative thalidomide was prescribed to pregnant women across 46 countries as a safe treatment for morning sickness and insomnia. It caused catastrophic birth defects in more than 10,000 children—shortened or absent limbs, malformed organs, and neurological damage. The manufacturer, Chemie Grünenthal, had never tested the drug on pregnant animals. In the United States, FDA medical officer Frances Kelsey refused to approve the drug despite aggressive lobbying from Richardson-Merrell, the American distributor. Her insistence on adequate safety data prevented what would have been thousands of American cases. This is the documented history of one of the worst pharmaceutical disasters in history and the regulatory failure that allowed it to happen.
In October 1957, the West German pharmaceutical company Chemie Grünenthal released a new sedative called Contergan. The drug's active ingredient, thalidomide, had been synthesized in 1954 by company chemists searching for an inexpensive anticonvulsant. When testing showed it had little effect on epilepsy, Grünenthal repositioned it as a sleeping aid and anti-nausea medication.
The company's marketing emphasized safety. Grünenthal claimed thalidomide was so benign it could be sold without prescription—and in Germany, it was. Promotional materials described it as "completely safe" and "non-toxic." Crucially, the company also marketed Contergan to pregnant women as a treatment for morning sickness.
The drug became phenomenally successful. By 1960, thalidomide was being sold in 46 countries under at least 37 different brand names. In West Germany alone, Grünenthal was selling over one ton of thalidomide per month. Licensed distributors marketed the drug across Europe, Canada, South America, Asia, and Africa. The British company Distillers sold it as Distaval. In Canada, it was marketed as Kevadon—the same brand name Richardson-Merrell planned to use in the United States.
But early warning signs were emerging. In 1959, German physicians began reporting cases of peripheral neuritis—nerve damage causing numbness, tingling, and pain in the extremities—among patients taking Contergan. By 1960, multiple reports had reached Grünenthal's medical director, Dr. Hans-Werner Pohle. Rather than investigating or restricting use, the company continued its aggressive marketing campaign.
Frances Oldham Kelsey joined the U.S. Food and Drug Administration as a medical officer in August 1960. Born in British Columbia in 1914, she had earned a PhD in pharmacology from the University of Chicago, where she had worked on research that identified the dangers of diethylene glycol—the compound that killed more than 100 people in the 1937 Elixir Sulfanilamide disaster that led to the 1938 Federal Food, Drug, and Cosmetic Act.
On September 12, 1960—just weeks after Kelsey started at the FDA—Richardson-Merrell submitted its New Drug Application for thalidomide, which it planned to market as Kevadon. The application was assigned to Kelsey as one of her first cases.
She immediately identified problems. The application contained inadequate data on the drug's absorption, metabolism, and excretion. More critically, Kelsey noted reports in British medical journals of peripheral neuritis in patients taking thalidomide. A December 1960 letter in The Lancet by Dr. A. Leslie Florence had described these cases in detail.
"The chronic toxicity tests...are not adequate to satisfy the legal requirements for approval of this application. We will expect you to supply additional information."
Frances Kelsey — Letter to Richardson-Merrell, November 1960Richardson-Merrell responded with frustration. Company executives believed Kelsey was being unreasonably obstinate. The drug had been approved in dozens of countries. Millions of doses had been dispensed. European regulators had found it safe. Why was this junior FDA reviewer creating obstacles?
The company's medical director, Dr. Terence Lasser, visited Kelsey's office repeatedly to argue for approval. Richardson-Merrell executives complained to FDA leadership, suggesting Kelsey was applying excessive scrutiny and creating bureaucratic delays. In internal company correspondence, executives described her as "unreasonable" and questioned her competence.
Kelsey refused to budge. She wanted data on the drug's potential effects during pregnancy. She wanted resolution of the peripheral neuritis reports. She wanted pharmacokinetic studies showing how the drug was metabolized. Each time Richardson-Merrell submitted additional data, Kelsey found it insufficient and requested more.
While awaiting FDA approval, Richardson-Merrell exploited a regulatory loophole. The company distributed thalidomide as an "investigational new drug"—a category that allowed physicians to prescribe unapproved medications to patients as part of clinical research, though regulations were far looser than they would later become.
The company's promotional materials for the investigational program specifically targeted obstetricians. Sales representatives encouraged doctors to prescribe Kevadon for morning sickness. Physicians were told the drug was awaiting final FDA approval and had an excellent safety record in Europe.
This distribution would later prove critical. While Kelsey's refusal prevented the drug's general marketing and avoided thousands of American cases, the investigational program meant that thalidomide still reached American patients. At least 17 American children would be born with thalidomide-related birth defects from this "investigational" distribution.
In Australia in mid-1961, obstetrician William McBride began noticing an alarming pattern. Over several months, multiple babies delivered at Crown Street Women's Hospital in Sydney had been born with severe limb malformations—short or absent arms and legs, a condition called phocomelia that typically occurred in about 1 in 100,000 births.
McBride reviewed his patient records and identified the common factor: he had prescribed thalidomide (marketed in Australia as Distaval) to the mothers for morning sickness during the first trimester. On June 20, 1961, he wrote to The Lancet warning of a possible connection. The journal published his letter on December 16, 1961.
Meanwhile in Hamburg, Germany, pediatric geneticist Widukind Lenz was investigating the same phenomenon. Between 1959 and 1961, Lenz had observed cases of phocomelia at rates hundreds of times higher than normal. He began systematically interviewing mothers of affected children, documenting their medication use during pregnancy.
The pattern was unmistakable. Mothers of children born with phocomelia had taken thalidomide during a critical window—days 34 to 50 of gestation, the period when limb buds form during embryonic development. The drug appeared to interfere with the formation of long bones, producing shortened or absent limbs. The severity of the defect correlated precisely with the timing of exposure.
On November 15, 1961, Lenz presented his findings at a pediatrics conference. The following day, he contacted Chemie Grünenthal directly, urging immediate withdrawal of Contergan from the market. The company initially resisted, questioning whether the evidence was conclusive. Executives suggested other factors might explain the birth defect cluster.
But the evidence was overwhelming. On November 26, 1961, Distillers withdrew Distaval from the British market. On November 27, Grünenthal withdrew Contergan from sale in Germany. Over the following weeks, the drug was pulled from markets worldwide.
By then, the damage was done. More than 10,000 children had been born with thalidomide-related defects. The malformations were severe: shortened or absent limbs, malformed ears, facial abnormalities, heart defects, kidney and gastrointestinal malformations, and neurological damage. Many children died in infancy. Those who survived faced lifelong disabilities.
In March 1962, as the scope of the European disaster became clear, American newspapers published the story. The focus quickly turned to Frances Kelsey, the FDA reviewer who had blocked Richardson-Merrell's application for 14 months.
Her refusal to approve thalidomide prevented what FDA officials estimated would have been between 2,000 and 10,000 American thalidomide births. The drug had been poised for major commercial success. Richardson-Merrell had invested heavily in marketing preparation. Sales projections were substantial.
But the American experience was not entirely without tragedy. The 2.5 million tablets Richardson-Merrell had distributed as investigational samples resulted in at least 17 American children born with thalidomide-related defects. The actual number may have been higher—some cases may have gone unreported or unrecognized.
The investigational distribution raised serious questions. Richardson-Merrell had provided the drug to physicians with minimal oversight, promoted it specifically for use in pregnant women, and continued distribution even as Kelsey raised safety concerns. The company did not recall the investigational tablets until March 1962—months after the European withdrawals.
On August 7, 1962, President John F. Kennedy awarded Frances Kelsey the President's Award for Distinguished Federal Civilian Service. In his remarks, Kennedy praised her "exceptional judgment" and said her work had prevented "a major tragedy" in the United States.
The ceremony was politically strategic. Senator Estes Kefauver had been conducting investigations of the pharmaceutical industry since 1959, documenting pricing abuses, questionable marketing practices, and the approval of drugs offering little therapeutic value. He had introduced legislation requiring drug companies to prove efficacy, not just safety, and establishing stricter testing standards.
The pharmaceutical industry had lobbied aggressively against Kefauver's bill. It had stalled in Congress through 1961 and into 1962. The industry argued that additional regulation would stifle innovation and that existing safety standards were adequate.
The thalidomide disaster changed the political calculus overnight. Public awareness of drug safety risks spiked. Media coverage was extensive. The image of babies born without limbs because a drug company had not tested adequately created political momentum that years of Kefauver's detailed testimony about pricing practices had not achieved.
"The increased vigilance in the Food and Drug Administration which this case exemplifies...is the kind of dedication to the public interest that makes our government work."
President John F. Kennedy — Award Ceremony Remarks, August 7, 1962The Kefauver-Harris Amendment was signed into law on October 10, 1962. The legislation fundamentally reformed American drug regulation. It required manufacturers to prove both safety and efficacy before approval. It established formal phases of clinical trials. It mandated informed consent for research subjects. It required companies to report adverse events. It gave the FDA authority to withdraw approved drugs if new evidence showed they were unsafe or ineffective.
The amendment was significantly weaker than Kefauver's original proposal—provisions addressing drug pricing and patent practices were largely eliminated through industry lobbying. But the safety and efficacy requirements represented a fundamental shift in pharmaceutical regulation.
In West Germany, criminal proceedings against Chemie Grünenthal executives began in 1967. The trial lasted two and a half years and became one of the longest criminal proceedings in German legal history. Prosecutors charged company officials with causing bodily harm through negligence and making false claims about the drug's safety.
The trial was abandoned in 1970 without convictions. Grünenthal agreed to pay 100 million Deutsche Marks to a compensation fund for victims. In exchange, the charges were dropped. Critics argued this denied victims accountability and set a precedent that pharmaceutical companies could pay their way out of criminal liability.
In the United Kingdom, families of affected children sued Distillers Company. The litigation dragged on for years. Distillers initially offered settlements that victims' advocates considered inadequate. The Sunday Times launched an investigative campaign examining internal company documents and challenging Distillers' claim that it had acted properly given the scientific knowledge of the time.
When The Sunday Times sought to publish its findings in 1972, Distillers obtained a court injunction blocking publication on the grounds the articles would prejudice ongoing litigation. The injunction remained in force for five years. The case eventually reached the European Court of Human Rights, which ruled in 1979 that the injunction violated freedom of expression protections.
Under sustained public pressure, Distillers agreed in 1973 to establish a £20 million trust fund for British thalidomide victims. The settlement came 12 years after the drug was withdrawn.
Richardson-Merrell faced litigation from American victims related to the investigational distribution. The company settled cases individually. Because the drug had never received formal FDA approval and the number of American cases was limited, Richardson-Merrell avoided the catastrophic liability it would have faced had Kelsey approved the application.
Internal documents revealed during litigation showed that Chemie Grünenthal had received reports of peripheral neuritis as early as 1959 but continued marketing Contergan without restriction or additional warnings. Medical director Hans-Werner Pohle received these reports and did not initiate studies to investigate the adverse events.
Documents also showed that when Widukind Lenz first contacted Grünenthal on November 16, 1961, with evidence linking thalidomide to birth defects, company executives initially dismissed his findings. The company withdrew the drug only after mounting external pressure made continued sales untenable.
At Distillers, internal records showed the company had relied primarily on Grünenthal's safety data rather than conducting extensive independent testing. Research director George Somers had not performed reproductive toxicology studies—but neither had most pharmaceutical companies at the time, because such testing was not required.
This raised a critical question: Should pharmaceutical companies conduct safety testing beyond minimum regulatory requirements, particularly when marketing drugs to vulnerable populations like pregnant women? The scientific methodology for reproductive toxicology existed in the late 1950s, even if it was not yet standard practice or legally required.
Richardson-Merrell's aggressive investigational distribution while pressuring Kelsey for approval demonstrated the tension between commercial interests and safety evaluation. The company distributed millions of tablets and specifically targeted obstetricians while the safety review was ongoing and unresolved.
Thalidomide established several foundational principles in developmental toxicology. It demonstrated that drugs could cross the placental barrier and affect fetal development. It showed that effects varied based on precise timing of exposure during organogenesis. It proved that a compound could be highly toxic to the developing embryo while causing minimal harm to adults.
The disaster also demonstrated the inadequacy of traditional toxicology testing. Thalidomide had been tested in adult animals and showed low toxicity. But the drug's mechanism of action—interfering with angiogenesis, the formation of new blood vessels critical during limb bud development—was not detected by standard toxicity studies.
Reproductive toxicology became mandatory worldwide following the thalidomide disaster. Drugs are now tested in pregnant animals across multiple species before human trials begin. Regulatory agencies require specific developmental toxicity studies examining effects on embryonic and fetal development, parturition, and postnatal development.
Ironically, thalidomide itself returned to medical use decades later. In the 1990s, researchers discovered the drug had powerful immunomodulatory and anti-angiogenic properties. It proved effective in treating certain complications of leprosy and, in 1998, was approved by the FDA for this use under an unprecedented risk management program. In 2006, it was approved for multiple myeloma, a blood cancer.
Modern thalidomide use involves extensive safeguards: mandatory pregnancy testing, contraception requirements, restricted distribution through specialized pharmacies, and registry systems tracking every prescription. The drug remains absolutely contraindicated in pregnancy.
Compensation for thalidomide victims has remained controversial. In Germany, the initial 100 million Deutsche Mark fund was widely considered inadequate given the severity of disabilities and lifetime care needs. The German government later established additional compensation programs, but survivors and advocates have argued that payments remain insufficient.
In the United Kingdom, the £20 million Distillers fund established in 1973 was supplemented by additional government payments, but British thalidomide survivors have continued to seek increased support as they age and face health complications related to their original injuries.
Chemie Grünenthal did not issue a formal apology until 2012—fifty years after the disaster. At a ceremony in Germany, company executives expressed regret, though they did not acknowledge legal liability. The apology was met with mixed reactions from survivors, some of whom appreciated the recognition while others viewed it as insufficient given the company's decades of denial.
Frances Kelsey continued working at the FDA until her retirement in 2005 at age 90. She spent much of her career working on regulatory policy and drug safety surveillance. She received numerous awards and honors, including induction into the National Women's Hall of Fame. She died in 2015 at age 101.
Her role in preventing the widespread American distribution of thalidomide remains the clearest documented case of a single government official's decision preventing a major public health catastrophe. The contrast between European countries where the drug was widely marketed and the United States where it was blocked provides as close to a controlled experiment as exists in pharmaceutical regulation—demonstrating what would have occurred without her intervention.
The thalidomide disaster established several principles that continue to define pharmaceutical regulation:
Pre-market safety testing must include reproductive toxicology. No drug is approved today without extensive testing in pregnant animals to assess potential effects on fetal development. This testing includes studies across multiple species and evaluation of effects at different stages of pregnancy.
Clinical trial oversight requires institutional structure. The loose "investigational new drug" category that allowed Richardson-Merrell to distribute 2.5 million tablets with minimal oversight was tightened significantly. Modern clinical trials require Institutional Review Board approval, informed consent, and FDA oversight of trial protocols.
Post-market surveillance is essential. The peripheral neuritis reports that reached Grünenthal as early as 1959 should have triggered investigation. Modern adverse event reporting systems—still imperfect—create formal mechanisms for identifying safety signals after drugs reach the market.
Regulatory independence requires institutional support. Kelsey's ability to resist industry pressure depended partly on her personal conviction but also on FDA procedures that allowed a reviewer to request additional data. Her case strengthened the institutional position of FDA reviewers to demand adequate evidence before approval.
The case also demonstrated limitations. The investigational distribution loophole meant that even without formal approval, thalidomide reached American patients. Regulatory systems designed for one country cannot prevent disasters originating elsewhere when drugs are marketed internationally without coordination. And compensation systems—whether through litigation or government programs—remain contentious decades after the fact.
More than 60 years later, survivors born with thalidomide-related disabilities continue to live with the consequences of decisions made by pharmaceutical executives and regulators in the late 1950s. The documents are public. The evidence of what was known and when is established. What remains contested is whether accountability was achieved and whether the lessons were sufficiently learned to prevent similar failures in the future.